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Abstract  
The effects of long-term administration of low doses of dexamethasone (DX) and prednisolone (PL) on 
the metabolism of endogenous corticosteroids were investigated in veal calves.  In addition to cortisol 
(F) and cortisone (E), whose interconversion is regulated by 11β-hydroxysteroid dehydrogenases 
(11βHSDs), special attention was paid to tetrahydrocortisol (THF), allo-tetrahydrocortisol (aTHF), 
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tetrahydrocortisone (THE) and allo-tetrahydrocortisone (aTHE), that are produced from F and E by 
catalytic activity of 5α and 5β reductases. A specifically-developed HPLC-ESI-MS/MS method 
achieved the complete chromatographic separation of two pairs of diastereoisomers (THF/aTHF and 
THE/aTHE) which, with appropriate mass fragmentation patterns, provided an unambiguous 
conformation. The method was linear (r2 > 0.9905; 0.5-25 ng mL-1), with LOQQ of 0.5 ng mL-1. 
Recoveries were in range 75-114%, while matrix effects were minimal. 
The experimental study was carried out on three groups of male Friesian veal calves: group PL (n = 6, 
PL acetate 15 mg/day p.o. for 31 days); group DX (n = 5, 5 mg of estradiol (E2) i.m., weekly, and 0.4 
mg/day of DX p.o. for 31 days) and a control group (n = 8). Urine was collected before, during (twice) 
and at the end of treatment. During PL administration, the tetrahydro-metabolite levels decreased 
gradually and remained low after the suspension of treatment. DX reduced urinary THF that persisted 
after the treatment, while THE levels decreased during the experiment, but rebounded substantially 
after the DX was withdrawn. Both DX and PL significantly interfered with production of F and E, 
leading to their complete depletion. Taken together, our results demonstrate the influence of DX and 
PL administration on 11βHSD activity and their impact on dysfunction of the 5-reductase pathway. In 
conclusion, profiling tetrahydro-metabolites of F and E might serve as an alternative, indirect but 
reliable, non-invasive procedure for assessing the impact of synthetic glucocorticosteroids 
administration. 
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1. INTRODUCTION  
Endogenous corticosteroids, mineralocorticoids and glucocorticoids, represent an essential 
physiological class of steroidal structures that are synthesised in the adrenal cortex. These hormones 
are involved in a wide range of pathophysiological processes, such as the stress response, 
inflammation, immune function, hydro-electrolyte balance, reproduction and behaviour (Vincenti, et al. 
2012). The most important glucocorticosteroid is cortisol (F), which exhibits hormonal activity; 
whereas, cortisone (E) is the inactive hormone that is produced from F by 11β-hydroxysteroid 
dehydrogenase (11β-HSD) (White et al, 2001) (Fig.  1.). There are two 11β-HSD isoforms: type I 
triggers the conversion of E into F, while type II regulates the conversion of F into E. F and E are 
metabolized to the corresponding A-ring reduced metabolites: tetrahydrocortisol (THF), allo-
tetrahydrocortisol (aTHF), tetrahydrocortisone (THE) and allo-tetrahydrocortisone (aTHE) by a two-
step reduction, firstly of the delta 4 double bond, catalyzed by 5α- or 5β-reductase, followed by the 
reduction of the 3-keto group, catalyzed by 3-oxoreductase (Draper &  Stewart, 2005).  Studies on 
human urine have shown that the F/E ratio can be used as a marker of inhibition of 11β-HSD type II 
(Tomlinson et al. 2007), while the (THF + aTHF)/THE ratio can be considered a marker of inhibition 
of 11β-HSD type I (Raffaelli et al. 2006; Courtney et al. 2008).  
However, due to the important role of natural corticosteroids in several bodily functions, they 
also have been exogenously administered to animals and humans in order to obtain health benefits and 
also to improve physical and growth performance. This has led to the chemical synthesis of 
corticosteroids with increased activity, for example, prednisolone (PL) and dexamethasone (DX). 
Introduction of a double bond in position C1–C2 of F and the formation of a conjugated π-electronic 
system of prednisolone results in significantly increased pharmacological activity extending the 
duration of glucocorticosteroid therapeutic effects. DX is a C9-fluorinated and C16-methylated PL 
derivative, characterized by pronounced glucocorticoid efficacy associated with a nearly complete loss 
of mineralcorticoid activity.  
Data from the Italian National Residues Plan (PNR) showed an increase in illegal use of DX, 
while particular attention was drawn to PL, as this corticosteroid may, in certain metabolic conditions, 
be produced endogenously (Arioli et al. 2010; Pompa et al. 2011). However, the persistent use of these 
substances requires a permanent commitment of public veterinary services for their prevention and 
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control. For this purpose, different analytical methods are commonly used, but the only method that is 
legally recognized is direct chemical analysis of the administrated substances, which, although specific 
and sensitive, has some limitations. Furthermore, the very quick biotransformation of PL and DX and 
very low dosage makes their detection particularly difficult. Therefore, new methodological approaches 
to reinforce veterinary controls are urgently needed (Cannizzo et al. 2011; Divari et al. 2011; Vascellari 
et al. 2012; Pegolo et al. 2015, Pirro et al. 2015).  
Focusing on the veterinary field, the most desirable action of hormones has always been to 
increase the economic benefit by reducing the costs and obtaining more products of animal origin with 
shorter production times. Synthetic corticosteroids administered to bovines, results in an improved feed 
conversion ratio and produce an increase in live weight. This effect probably depends on their direct 
action as glucocorticoids and on their interference with endogenous F synthesis and metabolism (Möstl 
et al. 1999). Quinkler et al. (2003) showed that activity of the “cortisol-cortisone shuttle” system is 
influenced by the presence of exogenous glucocorticoids, like DX and PL.  
The effects of administration of synthetic corticosteroids on the urinary profile of F has been 
investigated in humans in detail (Mazzarino et al. 2006). On the other hand, few studies have been 
devoted to investigate the correlation between natural and administered synthetic corticosteroids in 
order to identify indirect biomarkers for eventual treatments (Savu et al. 1996; Vincenti et al. 2009; 
Capolongo et al. 2007; Ferranti et al. 2011; Vincenti et al. 2012; Ferranti et al. 2013;  Nebbia et al. 
2014). Therefore, a method to identify natural corticosteroid levels in bovines could be an important 
tool for the control of illicit corticosteroid treatment in livestock production. Recently, we have 
published (Pavlovic et al. 2013) that PL treatment influenced 11β-HSD, which brought up questions 
about the impact of PL treatment on the THF and THE metabolic rates. Accordingly, the role and 
importance of reduced forms of F and E and their metabolic rates during treatment with exogenous 
glucocorticoids are lacking and remain to be established. 
In order to better understand the biological relevance of cattle’s 11β-HSDs and their activity in 
response to treatment with synthetic corticosteroids, it would be necessary to establish baseline levels 
of the endogenous corticosteroids. Remarkably, not many studies about the concentrations of F and E 
in bovine urine are present in the literature (Antignac  et al. 2002; Pavlovic et al. 2012; Ferranti et al. 
2013). In addition, due to their low concentrations, synthetic and/or (pseudo)natural corticosteroids are 
often not detectable in biological matrices by official methods. For both purposes, a highly sensitive 
and selective analysis is required. Our study was focused on the development of a quantitative HPLC-
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ESI-MS/MS method for simultaneous measurement of F, E, THF, aTHF, THE, aTHE, PL, Prednisone, 
(PN) and DX in bovine urine. Our analytical procedure could then be used to make a preliminary 
estimate of the effects of PL and DX administration on the amounts and corresponding ratios of 
targeted natural corticosteroids. This would consequently allow an evaluation of the utility of their 
quantification in studying either the activity of the enzymes responsible for their interconversion or any 
possible application to revealing the abuse of synthetic corticosteroids in bovine agriculture. This might 
be considered an important tool, which can be used for exposing illegal use of corticosteroids.  
 
2. MATERIALS AND METHODS 
2.1 Chemicals and reagents 
F, E, PL, PN and DX were purchased from Sigma-Aldrich (St. Louis, MO, USA) while THF, 
aTHF, THE and aTHE were obtained from Steraloids, Inc. (Newport, RI, USA). The internal standard 
PL-d6 (PL-d6) was from CDN Isotopes (Pointe-Claire, Quebec, Canada). All other chemicals were 
from Fluka Chemie GmbH (Buchs, Switzerland). Ultrapure water was obtained through a Milli-Q 
system (Millipore, Molsheim, France). Standard stock solutions were prepared in methanol (1 mg/mL) 
and stored at −40 °C. Working solutions were prepared daily by diluting the stock solutions with a 
methanol/water (50:50, v/v) mixture. Roche Diagnostics GmbH (Boehringer Mannheim, Germany) 
supplied beta-glucuronidase from Escherichia coli K 12 (EC 3.2.1.31) and β-
glucuronidase/arylsulfatase from Helix pomatia (EC 3.2.1.31 / EC 3.1.6.1). 
2.2 Sample preparation  
The sample purification was analogous to that previously established for human urine by 
Cuzzola et al. (2009) with slight modifications regarding bovine urine (Pavlovic et al. 2012). Briefly, a 
1 mL aliquot of filtered urine was  diluted with 2 mL phosphate buffer (0.2 M, pH 6.2) and incubated 
with 40 µL β-glucuronidase from E.coli at 55 °C for 4 h. Alternatively, during preliminary experiment 
we performed deconjugation with 20 μL of β-glucuronidase/sulphatase from Helix pomatia at 45°C for 
4 h. After cooling down to room temperature, 20 µL of 0.1 µg/mL internal standard was added for a 
final concentration of 2 ppb. Each sample was extracted using an Oasis HLB cartridge (3 mL, 60 mg, 
Waters) with Supelco SPE vacuum manifold. The HLB columns were conditioned by passage of 2 mL 
methanol followed by 2 mL water. The sample was deposited on the column and washed first with 
2 mL of 10% methanol and then with 1 mL of 2% ammonia in 50% methanol. The elution to recover 
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the corticosteroids of interest was performed with 2 mL of methanol. The eluate was evaporated under 
a stream of nitrogen and reconstituted in 1 mL of initial mobile phase.  
2.3 LC-MS/MS instrumentation and analytical conditions 
LC-MS/MS analysis was carried out on a Thermo Finnigan HPLC system (Thermo Fisher, San 
Josè, CA, USA), consisting of a Surveyor MS quaternary pump with a degasser, a Surveyor AS 
autosampler, a column oven and a Rheodyne valve with 20 μL sample loop. The mass spectrometer 
system was a TSQ Quantum triple quadrupole (Thermo Fisher Scientific, San Jose, CA, USA) 
equipped with an electrospray interface (ESI) set in the negative polarity ionisation mode. The analysis 
was performed in multiple reaction monitoring (MRM) mode. Acquisition data were recorded and 
elaborated using Xcalibur™ software from Thermo.  
Chromatographic separation was achieved using a Raptor (Restek) biphenyl column (150 x 2.1 
mm, 2.7 µm) with a Raptor (Restek) biphenyl 2.7 (5 x 2.1 mm) guard column, which was kept at 
30 °C. The mobile phase used in the chromatographic separation consisted of a binary mixture of 
solvents A (aqueous formic acid, 0.1%), and B (100% MeOH) at a flow rate of 200 μL/min. The 
gradient program began at 75% A changing to 40% A in 20th min. Subsequently, the mobile phase A 
rapidly decreased to 10% in next two minutes, which remained constant up to the 25th min. The mobile 
phase was returned to initial conditions at 28th min, with the equilibration time that included the 
interval from 28th to 35th min.  
Acquisition parameters were optimised in the ion spray mode with direct continuous pump-
syringe infusion of standard solutions of the analytes at the concentration of 1 μg/mL at a flow rate of 
the syringe of 10 µL/min and a pump flow rate of 100 µL/min in the ion source of the mass 
spectrometer. The optimised parameters were the following: capillary voltage 4000V; ion transfer 
capillary temperature 340 °C; and sheath and auxiliary gas (nitrogen) were fixed at 30 and 10 (arbitrary 
units), respectively. The collision gas was argon at 1.5 mTorr and the peak resolution of 0.70 Da 
FWHM was used.  
2.4 Assay validation  
 The proposed procedure was validated in order to evaluate the method in terms of specificity, 
linearity, sensitivity, precision, matrix effects and recovery.  
2.4.1 Specificity 
During preliminary experiments, urine from bovines that were variable in age, gender and breed 
were randomly analyzed. During those initial surveys, we found considerable number of samples with 
very low amounts (traces) of the endogenous compounds of interest: THF, THE, F and E. Furthermore, 
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in some samples it was not possible to detect any of them. Those samples were considered as blank 
samples for the specificity evaluation. We analysed an appropriate number of representative blank 
samples (n = 10) and checked for any interference (signals, peaks, ion traces) in the region of interest 
where the target analyte was expected to elute. The occurrence of possible interference from closely 
related substances (isomers, metabolites, degradation products, endogenous substances, matrix 
constituents) was tested by monitoring the MRM profiles of investigated compounds at the retention 
time intervals expected for their elution. The identification of corticosteroids performed by means of 
LC-MS/MS was done according to European Union guidelines (Commission Decision 2002/657/EC). 
The presence of the analytes being investigated was assessed by comparing the ratio of the 
chromatographic retention time of the analyte to that of the internal standard; the relative retention time 
of the analyte should correspond to that of the calibration solution at a tolerance of ± 2.5%. Three/four 
transitions were monitored for each analyte with a signal-to-noise ratio greater than three. All ion ratios 
of compounds from real samples were within the recommended tolerances when compared with the 
standards. A signal-to-noise (S/N) ratio greater than 3 was considered satisfactory in order to confirm 
the diagnostic ions. The quantifier ion was the one with the highest S/N value, which was not always 
the most abundant ion.  
2.4.2 Calibration curve preparation, linearity, and sensitivity 
A standard stock solution (1 mg/mL) of each corticosteroid was prepared in methanol. Standard 
spiking solutions at concentrations of 1 μg/mL were prepared by dilution of the stock standard solution. 
Bovine urine samples that in preliminary experiments did not revealed the presence of THF, THE, F 
and E were diluted with water (1:2) and exploited as blank matrices. Equal aliquots (2 mL) of a blank 
urine sample were fortified with seven different amounts of corticosteroids (0.5, 1, 2.5, 5, 10, 25 and 50 
ng mL-1) and a constant quantity of internal standard (2 ng mL-1) was subjected to the above described 
procedure. The analysis was performed in triplicate. The linear calibration curves were established by 
employing the IS calibration method: the ratio between the peak area of the analytes and the peak area 
of IS was plotted on the Y-axis with scalar concentration levels of standards plotted on the X-axis, 
leading to the equation Y = m * X + b. The linear fit was verified by squared correlation coefficients 
(R2). Sensitivity was determined as the lower limit of quantification (LLOQ). This parameter was 
calculated from the lowest point on the calibration curve under the following conditions: (1) the analyte 
response at the LLOQ should be at least 5 times the response compared to blank response; and (2) the 
analyte peak should be identifiable, discrete, and reproducible with a precision of 20% and accuracy of 
80–120% (FDA: Guidance for Industry Bioanalytical methods validation). The matrix-match 
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calibration curves that served as quality control samples (QCs) were repeated and were verified at the 
beginning of each working session involving the analysis of urinary excretion samples. 
2.4.3 Precision and repeatability 
The overall precision was broken down into two factors: instrumental and method precision. 
Instrumental precision was evaluated by six injections of each analyte at concentrations of 10 ng mL-1 
according to the optimal operative conditions. In this way, the repeatability of the instrumental system, 
expressed as relative standard deviations (RSD), was acquired. Method precision defined as intra-day 
repeatability of the assay, presented also as RSD, was determined by replicate analyses of blank urine 
samples (n = 6) fortified with 2.5 and 10 ng mL-1 of each compound. The intermediate (inter-day) 
method repeatability was determined on six consecutive days by processing the same samples used for 
intraday-precision.  
2.4.4 Matrix effects 
The matrix effect (ME) was examined by comparing the mean peak areas of the analytes and 
the IS between two different series. The first series consisted of blank urine samples spiked after the 
extraction with 5 ng mL-1 of each corticosteroid, while the second series consisted of reference 
standards. The ME was defined as follows: ME% = 100 × series 1/series 2, and it would indicate the 
possibility of ionisation suppression or enhancement for analytes and IS. An endogenous matrix effect 
is implied if the ratio is less than 85% or more than 115% (Matuszewski et al. 2003). 
 
2.4.5 Recovery  
Recovery data for all compounds were obtained in triplicate analyses of urine samples before 
and after adding known amounts of standards at lower (2.5 ng mL-1) and higher (10 ng mL-1) spiked 
concentrations. Recovery was calculated from the percentage difference between the quantitation 
results according to the following equation: Recovery (%) = 100 × [Conc(urine + spike) – Conc(urine)] / 
Conc(spike). 
2.5 Animal study  
The study was carried out on 19 male Friesian veal calves randomly assigned to three 
experimental groups. Group PL (n = 6) was administered PL acetate, 15 mg/day p.o. for 31 days; group 
DX (n = 5) was administered 5 mg of estradiol (E2) i.m., weekly for six weeks, and 0.4 mg/day of DX 
p.o., for 31 days starting from the second injection of E2. Group C (n = 8) was untreated. Urine was 
collected at days 0 (one week before treatment), 15, 29 and 40 in the early morning after spontaneous 
micturition by licensed veterinarians, taking care to prevent faecal contamination. The last sampling 
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was carried out three days after treatment suspension. The samples were divided into aliquots and 
stored at ˗80 °C until the analysis was performed. 
2.6 Statistical analysis  
According to the Shapiro-Wilk test, the data were not normally distributed in the majority of the 
groups tested, therefore, non-parametric statistical evaluations were used. The Friedman Repeated 
Measures Analysis of Variance on Ranks, followed by all pairwise multiple comparison procedures 
(Tukey's Test) were used to check the differences between the medians of the three datasets. The 
statistical analyses were performed using Microsoft Excel spreadsheets and Sigma Stat (Statistical 
Analysis System, version 12.5) statistical software package (Jandel Scientific GmbH, Erkrath, 
Germany). A P-value < 0.05 was defined as the level of statistical significance. 
 
3. RESULTS AND DISCUSION  
Corticosteroids, when administered to promote the growth of food production animals, usually 
are given in small doses over a relatively long time period. Because of their low concentrations and the 
fact that there is only limited understanding of their metabolism, the determination of exogenously 
administered corticosteroids remains difficult and rather problematic. The question that arises is 
whether the absence of these substances actually means that animals were not subjected to illicit 
treatment during breeding. An answer on this question cannot be given with certainty; studies on the 
impact of synthetic analogues on metabolism of endogenous glucocorticosteroids would perhaps 
provide some explanations. Therefore, the accurate and precise measurement of endogenous 
corticosteroids in bovine urine can be considered a potentially powerful tool in the identification of 
cattle that received illegal glucocorticoid treatments. 
For this purpose, we employed an HPLC–ESI-MS/MS technique, which was preceded by 
convenient sample preparation methodology (the hydrolysis and SPE extraction). Sample preparation 
was generally conducted analogously to our previously published procedure (Pavlovic et al. 2012) with 
some aspects that were studied in more detail. 
3.1 Enzymatic hydrolysis  
Based on previous research and our own experience, we first studied the necessity of the 
deconjugation process of eventually present glucuronide/sulphate conjugates. As far as bovine urine is 
concerned, the greater part of tetrahydro-metabolites are excreted predominantly as glucuronide 
conjugates, while F and E are most prevalent in their free form (Antignac et al. 2002). Arioli et al. 
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(2012) showed that, as far as PL is concerned, hydrolysis is not indispensable, as this corticosteroid is 
present almost exclusively in its free form. Taking all of this into account, we chose to perform our 
analysis using the most specific enzyme (Escherichia coli K 12 β-glucuronidase) to liberate the 
tetrahydro-corticosteroids. Therefore, the levels reported herein represent the sum of free and 
glucuronidated forms. This is an important point of clarification, as it can be speculated that alternative 
methods that hydrolyse both glucuronide and sulphate conjugates may cause an elevation in final 
concentrations. To exclude this type of doubt, during preliminary experiments, we performed the 
simultaneous cleavage of glucuronides and sulphate conjugates by applying Helix pomatia juice as the 
enzyme source. The concentration did not vary significantly (less 5% for all compounds), while 
heterogeneous properties of the Helix pomatia mixture provoked substantial matrix effects, pronounced 
background noise and a lower S/N ratio. We concluded that the sulphatase activity in addition to 
glucuronidase activity was not essential in this case.  
Special attention was dedicated to aTHF as it has been reported that its glucuronides require 
more extreme conditions to be cleaved (Cuzzola et al. 2014) and because in our previous study it was 
not found (Pavlovic et al. 2012). Hydrolysis experiments of urine samples were carried out varying the 
incubation time (4h, 8h and 12h) and the temperature (37oC, 45oC and 55oC) but once again, this 
metabolite aTHF was not detected in our bovine samples. The same was noticed for aTHE. Finally, the 
temperature and duration of hydrolysis were optimised to 40 μL of enzyme solution at 55 °C for 4 h 
(Fig.  2). No substantial enhancement in yield of any corticosteroids was observed when any of these 
parameters was increased.  
3.2 Sample SPE purification 
Sample purification through an Oasis HLB cartridge was designed to quantitatively extract the 
corticosteroids of interest and minimise interferences present in the urine matrix. The SPE procedure 
that we applied was similar to that previously reported for human urine (Cuzzola et al. 2009), with 
necessary adjustments for bovine urine (Pavlovic et al. 2012). A particularly important modification 
was the employment of just 1 mL of bovine urine. Greater initial sample volumes, although they 
provided higher absolute responses, sometimes caused more pronounced background noise and (in a 
few cases) presented interfering peaks.  
3.3 Optimization of mass spectrometry acquisition and chromatographic separation 
Fragmentation patterns of corticosteroids were studied in ESI (-) mode where pseudo-molecular 
ion species were present as formic acid adducts at [M+HCOO]-. After preliminary trials, in full-scan 
mode from 50 to 500 m/z, the minimum three product ions with the higher S/N ratio for each analyte 
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and internal standard were chosen for identification. The diagnostic product ions (among which is the 
ion for quantification), the relative intensities, and the collision energies (CEs) are reported in Table 1 
and Fig.  3. The precise adjustment of CE for each MRM was performed in order to reach the highest 
sensitivity and specificity for each compound. However, the fragmentation of some analytes that had 
equal molecular mass (cortisone and PL for example) was careful studied in order to enhance the 
capabilities of the method, avoiding the common transition. The m/z-values of the selected parent and 
daughter ions used for MS detection were generally in agreement with those previously reported by 
Chiesa et al. (2014). Special consideration was focused on fragmentation of the tetrahydro-metabolites, 
as there is limited number of publication that deal with the behaviour of their formic acid adducts in an 
ESI(-) source (Cuzzola et al. 2009). Our MS/MS conditions were tuned to achieve a mass-
spectrometric profile with four characteristic ions, providing the specific product ion ratios that were 
used for confirmation purposes. The most abundant product ion that corresponds to the cleavage of the 
side chain and loss of formaldehyde [M–CH2O–H]- were m/z = 333 and m/z = 335, respectively, for 
THF and THE, which is in agreement with the recently published paper from Zhai et al. (2015). The 
selection of the most abundant product ion was the best option in order to optimize the sensitivity and 
specificity of the tetrahydro-metabolite characterisations. Interestingly, it was not case for F and E. The 
quantifiers that were chosen for them are other than the most abundant ions. The reason is simple: the 
most intense fragments from F and E are formed by cleavage of the C20–C21 bond (ions m/z = 329 and 
m/z = 331, respectively), and are also present in some interfering co-eluting compounds. The further 
fragment (319) of THF is most probably formed when [M–CH2O–H]- loses the methane (16Da) giving 
[M–CH2O–CH4–H]- which is similar to the finding reported for PL (Ferranti et al. 2011;  Savu et al. 
1996). The ion m/z = 301 is produced when H2O subsequently is removed from the steroid moiety 
(probably via the hydroxyl group from C11) leading to formation of the [M–CH2O–CH4–H2O–H]- ion. 
These findings are analogues with those that Mitamura et al. (2014) have recently reported describing 
transitions of different tetrahydrocorticosteroid sulphates. Regarding the THE, complete elimination of 
the side chain (cleavage of C17–C20 bond) provided a fragment at m/z = 305, while for the product ion 
at m/z = 261 structural assignments seem to be too speculative. The molecular [M–H]– ions (m/z = 363 
and m/z = 365) were identified in second transition, and their appearance was enabled by applying a 
low collision energy. Turpeinen et al. (2006), with methanol and water as the mobile phase, used those 
deprotonated molecular ions as a parent in the LC-MS/MS determination of tetrahydro-corticosteroids. 
Those authors also obtained a slightly different mass spectrum for two tetrahydro-isomers, which in our 
case was not possible.  
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Attempts were made to acquire different fragmentation patterns and thus to distinguish aTHF 
from THF and aTHE from THE, but unfortunately these were without success. Therefore, the 
chromatographic column and gradient elution programme was carefully optimised until it permitted the 
complete separation of the isomers (Fig. 3). For this purpose, we used a new Raptor Biphenyl Column 
that employs a phenyl-hexyl stationary phase, with an innovative biphenyl ligand, which is the first 
time it has been used in corticosteroid separation. The unique composition of biphenyl groups in 
sterically favourable positions improves the interactions with steroid fused-ring moieties, resulting in 
baseline separation of very structurally similar corticosteroids, including two pairs of diastereoisomers. 
The separation of aTHF and THF was relatively easy to achieve, first of all because of the increased 
polarity due to presence of three hydroxyl groups. The OH-group from C11 seems especially important 
as it interacts in a particular manner with the rest of the steroid moiety, which subsequently provokes 
distinct distribution of aTHF and THE between the mobile and stationary phases. Secondly, aTHF is a 
conformer where the A/B rings are joined though two equatorial-type bonds (trans-decalin type) 
whereas an axial-equatorial union gives the cis-decalin form. The separation of THE and its allo-isomer 
is an actual problem, not easily overcome and this is related to the C11 keto function. That is why THE 
and aTHE frequently are determined in human clinical practice as a combination.  More often, only 
THE is considered as the reduced metabolite of E while the level of aTHE is ignored (Główka et al. 
2010). The reason for such simplification may be the much lower level of aTHE in comparison to THE 
in human urine (Vierhapper, 2000). However, with our chromatographic conditions, baseline 
separation of those isomers was fully accomplished because, analogously to aTHF/THF, the biphenyl 
column is capable of chromatographically distinguish A/B ring conformers. 
3.4 Method validation  
Specificity and selectivity were evaluated as described in the materials and methods section, 
applying the Commission Decision 2002/657/CE. Blank samples (n = 10) were analysed and did not 
show any interference (signals, peaks, ion traces) in the region of interest, where the target analytes 
were expected to be. The relative retention time of the analytes corresponded to that of the standards, 
with a tolerance of ± 2.5%. Relative intensities of the product ions, expressed as a percentage of the 
intensity of the most intense ion, corresponded to those of the reference analyte. The relative intensities 
of the detected ions were within the permitted tolerances: the ion ratio of the product ion with relative 
intensity greater than 50% did not exceed the tolerance of 20%. Nonetheless, if relative ion intensity 
was in ranges either 20-50% or 20-10% the deviance in intensity was not allowed to be higher 
than 25% and 30%, respectively. 
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Seven concentration levels with three replicates each were used to build the regression line 
using the least square method. The calibration curve equations were used to calculate unknown 
concentrations in real urine samples of bovines enrolled in the experimental study. Regression 
coefficients of the curves showed very good linearity for all compounds (Table 2). The LLOQ values 
(Table 2) indicated that this method could be used for confirmation purposes, as recommended 
maximal residual levels allowed in urine are set at 2 ng mL-1 for DX ( CRL Guidance Paper, 2007) and 
5 ng mL-1 for PL (PNR).  
Precision, defined as the closeness of agreement between independent test results obtained 
under the stipulated conditions, is herein expressed as the repeatability. The intra-repeatability was 
satisfactory, with the relative standard deviation (RSD) ranging from 6% to 11%, whereas analysis of 
inter-day repeatability resulted in slightly higher variability (up to 20%). Instrumental precision was 
between 8% and 17% for all analytes. These results show good repeatability, indicating a stable 
instrumental response as far as the performance of the HPLC-ESI-MS/MS system is concerned.  
The overall recovery of the method, conducted on real urine samples with predetermined 
corticosteroid concentrations attained by adding known amounts of standards, ranged between 75 and 
114% as presented in Table 3. The two main reduced steroids (THF and THE) had the lowest recovery 
rates, almost certainly because of it particular structure and conformation. Those steroids belong to the 
5α-cholestan series with the cis positioning between A/B ring causing that steroidal structure is not 
linear as for F and E e.g., but slightly bended. This reduction in overall molecule surface could, in 
some extend, compromise efficient retention on hydrophilic–lipophilic balanced polymers from SPE 
Oasis. 
Assessment of matrix effects is mandatory in the validation of a quantitative assay using 
HPLC-ESI-MS/MS in biological samples, since endogenous impurities can affect the ionization 
process and may reduce or increase the efficiency of formation of the desired analyte ions. At the same 
time, the SPE purification step can be indirectly validated. Our study documented the absence of a 
significant matrix effect, with aTHF being the analyte that had the most evident ion suppression. This 
is obviously affected by the presence of electrolytes and ionisable co-eluting species, as this steroid is 
first to be eluted. Nevertheless, as other validation data, such as sensitivity and linearity, were 
acceptable and indicated good performance of the developed method, this was not considered a 
drawback for accurate determination. 
3.5 The impact of dexamethasone and prednisolone on endogenous corticosteroids production: 
real sample analysis  
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An important objective of this study was to apply the developed method to real urine samples 
from veal calves enrolled in an experimental treatment consisting of long-term PL and DX 
administration. The first group that we considered was the control group that did not receive any 
therapy (Table 4). It is worth noting that PL was detected in urine of control animals: median values 
were 0.72 and 0.74 ng mL-1 at the second and third time points, respectively. This supports the theory 
that PL can be produced as an endogenous substance, at least for healthy Friesian veal calves. The 
concentrations found are extremely low and, in some of our samples, barely detectable. Up to now, it 
has been demonstrated that PL could be generated in food-producing cattle by physiological metabolic 
processes, possibly under extremely stressful conditions, such as transport and slaughter, or by faecal 
contamination, as is supported by a few recent studies (Arioli et al. 2010; Ferranti  et al. 2011; Pompa 
et al. 2011). On the basis of these results and the opinion of the European Reference Laboratory, the 
Italian Ministry of Health has recently enacted a new disposition: a bovine urine sample is considered 
non-compliant for PL only when its concentration exceeds 5.0 ppb (Circular of Ministry of Health, 
2012).  Recently, evidence has been provided that veal calves, besides endogenous PL production, 
revealed remarkable F and E urine concentrations as a response to extremely stressful conditions ( 
Ferranti et al, 2013). The presumption was made that PL might be formed by the dehydrogenation of F 
due to the enterohepatic circulation process. Although the determination of the PL biosynthetic route 
was beyond the aim of this research, and bearing in mind that our experiment was designed to avoid 
any type of stress, it can be noticed that in the control group PL appeared along with higher F and E 
concentrations: on day 15, those levels were 4.07, 9.89 and 0.72 ng mL-1 for E, F and PL respectively. 
PN residue was found only in one urine sample without any correlation to the highest levels of PL, F or 
E and it is probably due to some individual metabolic state of the animal at this time point.  
The data obtained from the control group provides preliminary information regarding the 
physiological levels of A-ring reduced F and E in non-treated, healthy veal calves, which has not been 
reported in the literature up to now. The measured values exhibited a high intergroup variation having 
THF and THF values ranging from 7.54–49.22 and 1.80–22.38 ng mL-1, respectively. In general, no 
official threshold has been established for natural hormone concentrations in bovine urine, mainly due 
to the fact that concentrations of naturally occurring hormones are highly variable and depend on the 
type of animal product, breed, gender, age, disease, medication and physiological condition (Antignac 
et al. 2002; Angeletti et al. 2006; Pleadin et al. 2011). In our research, aTHF and aTHE were below the 
detection limit, unlike results obtained for human urine (Cuzzola et al. 2014). These findings imply that 
for the natural corticosteroids in bovine, 5β-reduction predominates over the 5α-reductase activity. The 
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virtual absence of 5α-reduction of F and E is represented visually in the MRM chromatograms 
illustrated in Fig. 3. This indicates that there are substantial differences between human and bovine 
production of F and E A ring metabolites. 
Data obtained from veal calves treated with PL revealed the low concentrations of this 
glucocorticoid in most, but not all, urine samples collected in the course of treatment (Table 5), which 
confirms previous findings (Cannizzo et al. 2011). Despite the significantly 20-times higher dose 
administered with respect to DX, it is metabolised much faster and apparently, the depletion pattern 
does not depend on the administered dose. Three days after treatment suspension, PL was still detected 
in half of the samples. In the middle of treatment a very low concentration of PN was found (day 25), 
as it is formed as a metabolite from the interconversion of PL.  
PL significantly interfered with the production of F and E, leading to complete depletion of 
both. Nebbia et al. (2014) also observed a decrease in F and E levels in finishing bulls and cows after 
therapeutic treatment with PL acetate. This is to some extent in contrast with our preliminary study 
(Pavlovic et al. 2013) where no differences were found in the F and E excretion time course during PL 
treatment in male cattle. The plausible explanation for this discrepancy is that those experimental 
subjects differed in age and consequently in metabolism (veal calves are not yet ruminant). Although in 
both experiments the same dosage (15 mg/day for 30 consecutive days) of PL was administered, in veal 
calves it resulted in approximately double the dose relative to the animals' weight, which averaged 60 
kg for veal calves vs. 120 kg for beef cattle. Furthermore, considerable impact could be attributed to a 
different sampling schedule, since the last time point in our previous experiment was at slaughter, 
which intensified the extremely stressful situation. As was mentioned above, heavy stress conditions 
apparently favour endogenous PL production that is usually accompanied by an increase in urinary 
concentrations of F and E (Bertocchi et al. 2013; Ferranti et al. 2013), while exogenous administration 
of PL is likely to reduce the production of these main endogenous glucocorticoids. Our results confirm 
this hypothesis and are enriched with monitoring of the levels of F and E  A-ring reduced metabolites.  
As far as THF is concerned, its concentration significantly and gradually decreased during PL 
treatment, and remained low three days after the drug was discontinued. The THE levels showed a 
tendency to decline, but without statistical significance. Consequently, the THF/THE ratio remained 
unaffected. This indicated that it was better to consider the absolute values of THF and THE instead of 
their molar ratio. For this purpose, reference or threshold levels need to be introduced. So far, the 
metabolic fate of exogenously administered PL is relatively unknown, although some very important 
studies have been conducted recently (Vincenti et al. 2012; Ferranti et al. 2013; Nebbia et al. 2014). 
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The evident decrease in A-ring reduced F and E metabolites during the course of PL treatment may 
represent a new approach that would discriminate between exogenous and endogenous PL origin.  
Quantitative data from the urine samples in animals treated with DX are reported in Table 6. 
This drug was not identified at the first check-up (day 15), but a substantial amount was found in all 
samples collected at day 25. The results obtained in our experiments could be, only in limited extent, 
compared to the ones observed in previous studies, mostly because of the striking differences in both 
dosage and duration of DX administration. The elimination kinetics were in line with previously 
published data  regarding the grow-promotion protocol (Vincenti, et al. 2009). The values obtained are 
comparable with that obtained in beef cattle (Cannizzo et al. 2011) especially when it comes to the 
amount of drug dosed per kg of animal body weight: 0.4 mg/day for veal calves vs. 0.7 mg/day for 
beef. The main differences were observed in the samples taken after suspension of the treatment: in 
previous work no detectable residues were found six days after drug withdrawal, whereas in this study, 
approximatively the same quantity detected on day 25 was also measurable three days after the end of 
treatment (day 40). This might be due to the slightly different experimental design, such as the cattle 
breeds (Friesian vs. Charolaise) and animal age (veal calves vs. beef). However, the sampling schedule 
after the end of the treatment (sixth vs. third day) has to be taken as the more plausible reason for those 
findings. Apart from the fact that it is well known that DX reduces F levels (Ljung et al. 1996; Vincenti  
et al. 2009; Ferranti et a 2011; Ferranti et al. 2013), the withstanding result from this group is that the 
low dosage of DX given daily p.o. was capable of completely depleting E and F. This method of drug 
administration could accomplish circulating steady state concentrations of DX capable of influencing 
the production of endogenous F much more than the higher intermittent intramuscular dose applied by 
Capolongo et al. (2007). The same studies also indicated the urinary free 6β-F/F as new promising 
screening test for detection of long-term DX illicit administration in cattle, but very resent data suggest 
that it could not be a reliable biomarker of illicit DX treatment as presence of 6β-F was not always 
registered (Famele et al. 2015).  
No detectable residues were found as far as THF is concerned, at the same sampling points as 
for F and E whereas THE expressed an interesting behaviour: after complete depletion at day 25, it 
appeared again in urine three days after the withdrawal of DX. This indicates that low dose 
administration of DX reversibly influences the metabolic pathway, which involves the two-step 
enzymatic transformation of E to THE by 5β-reductase, followed by the reduction of the 3-keto group 
catalyzed by 3α-oxoreductase (Draper & Stewart 2005). The short withdrawal period was enough to 
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restore enzymatic activity responsible for E to THE transformation, while it was not the case for the 
corresponding F to THF conversion. In addition, appearance of THE after DX removal is attributable to 
prompt reestablishment of 11β-HSDII activity, as well. This finding qualifies THF and THE as 
promising biomarkers that could be useful to the evaluation of DX abuse in cattle. Also, it remains to 
be established whether the complete disappearance of four natural corticosteroids in the course of DX 
treatment is associated with up‐regulation of both 11β‐HSDs in adrenal tissue (Cannizzo et al. 2013). 
 
4. CONCLUSIONS 
 
The development of analytical procedures based on the HPLC-ESI-MS/MS technique was 
indispensable to carry out investigations regarding the effects of DX and PL on the metabolism of the 
main endogenous glucocorticosteroids. The method validation requirements were completely fulfilled: 
the method was precise, accurate, sensitive and reliable for the above mentioned scope. The presented 
data provide an indication of the utility of the method for the assessment of 11-hydroxysteroid 
dehydrogenases and 5β-reductase activity associated with DX or PL treatment. Further studies are 
needed to understand the mechanisms of DX and PL action on F and E. In particular, it would be 
interesting to study more in-depth the origin of the specific behaviour of the corresponding tetrahydro-
metabolites during DX and PL administration. Furthermore, it remains to be clarified whether results 
observed herein might represent a promising tool for the detection of illicit treatment of bovine with 
DX or PL.  
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Figure captions 
 
Fig.  1. Interconversion of cortisol/cortisone by 11β-hydroxysteroid dehydrogenases (11β-HSDs) and 
formation of their main A ring reduced metabolites: tetrahydrocortisol and tetrahydrocortisone. Dashed 
arrows denote the probable metabolic route that would lead to corresponding diastereoisomers allo-
tetrahydrocortisol and allo-tetrahydrocortisone formation. The structures of syntactic 
glucocorticosteroids are presented as well. 
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Fig.  2. Influence of temperature and incubation time on the extent of enzymatic hydrolysis of 
conjugated corticosteroids in 1 mL of calves’ urine at pH 6.2 with 40 µL β-glucuronidase from 
Escherichia coli K 12 (EC 3.2.1.31). The highest yield of hydrolysis for each compound is fixed as 
100% and all other values are given as a % of this yield. 
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Fig.  3. HPLC–ESI-MS/MS chromatograms and related MS spectra of the studied corticosteroids in a 
blank urine sample spiked at the concentration of 5 ng mL-1. 
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Table 1. Precursor ions and specific diagnostic ions with tube values and collision energies (CE) of the 
targeted corticosteroids. Ions for quantification are in bold.  
Analyte Precursor ion (m/z) Product ions (m/z) Tube lens 
F  407 282(37),297(33),331a(20) 74 
E  405 137(45), 301 (22), 329a(19) 359(13) 72 
PL  405 187(30), 280(35), 329a(19) 71 
PN 403 149(45), 299(21), 327a(19) 357(12) 52 
aTHE /THE 409 261(37), 305(25), 333(20),363(15) 77 
aTHF / THF 411 301(37), 319(29), 335(21),365(15) 75 
DX 437 307(33), 361a(20),391(14) 81 
PL-d6 411 284(37), 299 (32), 333a(19) 77 
aMost abundant product ion  
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Table 2. Validation data summary: linearity, LLOQ and repeatability  
Analyte Calibration curve (n=3) R2 LLOQ 
Spiked 
level 
(ngmL-1) 
Repeatability 
intra-day  
(RSD; 
(n=6) 
inter-day  
(RSD; 
(n=6) 
F Y =0.509 (± 0.011) X - 0.326 (± 0.247) 0.9905 0.5 
2.5 7 13 
10 5 17 
E Y = 0.179 (± 0.002) X - 0.080 (± 0.047) 0.9971 0.5 
2.5 8 12 
10 10 15 
PL Y = 0.082 (± 0.001) X - 0.060 (± 0.022) 0.9972 0.5 
2.5 6 17 
10 8 14 
PN Y = 0.286 (± 0.004) X  0.258 ((± 0.080) 0.9968 0.5 
2.5 10 17 
10 11 18 
aTHF Y = 0.074 (± 0.001) X -0.041 (± 0.022) 0.9957 0.5 
2.5 7 20 
10 8 18 
THF Y = 0.090 (± 0.001) X - 0.065 (± 0.029) 0.9944 0.5 
2.5 6 12 
10 5 19 
aTHE Y = 0.484 (± 0.007) X - 0.319 (± 0.153) 0.9960 0.5 
2.5 5 12 
10 9 14 
THE Y = 0.405 (± 0.004) X - 0.206 (± 0.089) 0.9980 0.5 
2.5 9 16 
10 10 16 
DX Y = 0.632 (± 0.009) X - 0.598 (± 0.191) 0.9963 0.5 
2.5 7 12 
10 11 13 
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Table 3. Recovery data for natural and synthetic corticosteroids enrolled in study  
 
Analyte Urine (ng mL-1) Spiked (ng mL-1) Urine + Spike  (ng mL-1) Recovery (%) 
F 1.4 
2.5 2.4 114 
10 9.8 110 
E 2.3 
2.5 4.3 111 
10 12.4 116 
PL ND 
2.5 2.8 112 
10 11 110 
PN ND 
2.5 2.33 93 
10 8.9 89 
aTHF ND 
2.5 2.4 75 
10 8.8 88 
THF 7.2 
2.5 9.85 105 
10 16.4 92 
aTHE ND 
2.5 1.9 76 
10 8.9 89 
THE 4.8 
2.5 6.8 79 
10 15.0 102 
DX ND 
2.5 2.1 84 
10 10.8 108 
Standard solutions (spike) were added to a urine sample with predetermined corticosteroid 
levels. The resulting concentration of the mixture (urine + spike) was determined. The 
concentrations presented are means of triplicate analysis.  
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Table 4. Concentrations of corticosteroids in control bovine urine collected during the experiment. 
Data are reported as the median (ng mL-1) with corresponding 25th–75th percentile. Number of 
samples/number of positive findings are given in parenthesis.  
Corticosteroids Day 0 Day 15 Day 29 Day 40 Statistical differences 
THF 
13.00 
7.91-23.04 
(8/8) 
17.75 
8.42-49.22 
(8/8)
17.26 
7.54-24.03 
(8/8)
12.36 
9.78-17.43 
(8/8)
NS 
THE 
6.65 
2.74-9.70 
(8/8) 
6.99 
2.77-14.95 
(8/8) 
7.20 
1.80-10.89 
(8/8) 
15.42 
9.15-22.38 
(8/8) 
NS 
THF/THE 
2.36 
1.65-3.82 
(8/8) 
3.04 
2.50-3.89 
(8/8) 
2.76 
2.21-4.18 
(8/8) 
0.94 a, b, c 
0.71-1.13 
(8/8) 
P = 0.003 
F 
3.70 
1.42-5.80 
(8/8) 
4.07 
2.82-5.27 
(8/8) 
1.7 
1.77-3.80 
(8/5) 
3.13 
2.71-6.55 
(8/8) 
NS 
E 
6.99 
2.29-9.15 
(8) 
9.89 
6.29-13.34 
(8) 
3.28 d 
1.56 -9.13 
(8)
2.18 a 
1.60-3.01 
(8)
P = 0.011 
F/E 
0.65 
0.53-0.69 
(8/8) 
0.41 
0.39-0.44 
(8/8) 
0.53 
0.45-3.76 
(8/5) 
1.78 a, b, c 
1.47-2.25 
(8/8) 
P = 0.003 
PL 
0 
0-0.76 
(8/2) 
0.72 
0.63-0.79 
(8/7) 
0.74 
0-1.32 
(8/5) 
0 
(8/0) NS 
PN 0 (8/0) 
0 
(8/8) 
5.6 
(8/1) 
0 
(8/0) NP 
DX 0 (8/0) 
0 
(8/0) 
0 
(8/0) 
0 
(8/0) NP 
NS – not significant, NP – not performed
Friedman Repeated Measures Analysis of Variance on Ranks was used to test the significance 
between the groups. When the analysis was significant, to isolate the group that differs from the 
others, pairwise multiple comparison procedures (Tukey's Test) were applied. Following 
subscripts refer to statistically significant pairwise difference: a Day 0 vs Day 40; b Day 15 vs Day 
40; c Day 29 vs Day 40; d Day 0 vs Day 29 
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Table 5. Urinary concentrations of corticosteroids collected during prednisolone treatment. Data are 
reported as the median (ng mL-1) with corresponding 25th–75th percentiles. Number of 
samples/number of positive findings are given in parenthesis.  
Corticosteroids Day 0 Day 15 Day 29 Day 40 Statistical differences 
THF 
14.26 
8.06-18.62 
(6/6) 
6.18 
4.74-8.75 
(6/6) 
2.90 a 
1.11-4.87 
(6/6) 
2.40 b 
1.96-6.94 
(6/6) 
P = 0.004 
THE 
11.93 
5.73-20.31 
(6/6) 
3.86 
1.87-4.80 
(6/6) 
2.40 
2.01-3.30 
(6/6) 
4.40 
1.9-6.9 
(6/6) 
NS 
THF/THE 
1.09 
0.79-2.66 
(6/6) 
2.10 
1.48-4.80 
(6/6) 
0.74 
0.53-1.93 
(6/6) 
1.10 
0.54-1.26 
(6/6) 
NS 
F 
4.41 
2.69-8.27 
(6/6) 
1.07 
0.91-1.28 
(6/6) 
0 a 
(6/0) 
0 b 
(6/0) 
P = 0.001 
E 
4.27 
1.83-8.25 
(6/6) 
1.49 
1.01-2.04 
(6/6) 
0 a 
(6/0) 
0 b 
(6/0) 
P = 0.001 
F/E 
1.66 
0.44-2.33 
 (6/6) 
0.76 
0.66-0.97 
(6/6) 
/ / NP 
PL 0 (6/0) 
0.67  
0.46-1.19 
(6/5) 
2.48 a 
1.05-6.18 
(6/6)
0.39 c 
0-1.07 
(6/3)
P = 0.001 
PN 
0 
(6/0) 
0 
(6/0) 
0.80 
0-2.34 
(6/3) 
0 
(6/0) NS 
DX 0 (6/0) 
0 
(6/0) 
0 
(6/0) 
0 
(6/0) NP 
NS – not significant; NP – not performed
Friedman Repeated Measures Analysis of Variance on Ranks was used to test the significance 
between the groups. When the analysis was significant, to isolate the group that differs from the 
others, pairwise multiple comparison procedures (Tukey's Test) were applied. Following 
subscripts refer to statistically significant pairwise difference: a Day 0 vs Day 29; b Day 0 vs Day 40; 
c Day 29 vs Day 40  
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Table 6. Urinary concentrations of corticosteroids collected during dexamethasone treatment. Data 
are reported as the median (ng mL-1) with corresponding 25th–75th percentiles. Number of 
samples/number of positive findings are given in parenthesis.  
Corticosteroids Day 0 Day 15 Day 29 Day 40 Statistical differences 
THF 
19.21 
10.86-25.1 
(5/5) 
18.83 
5.41-29.34 
(5/5) 
0 a 
(5/0) 
0 b, d 
(5/0) 
P = 0.004 
THE 
10.25 
8.41-16.61 
(5/5) 
9.09 
1.24-14.25 
(5/5) 
0 a, c 
(5/0) 
5.08 
4.00-5.51 
(5/5) 
P = 0.011 
THF/THE 
1.76 
0.99-2.24 
(5/5) 
2.31 
1.93-8.06 
(5/5) 
/ / NP 
F 
4.40 
3.50-9.90 
(5/5) 
1.00 
0.81-9.22 
(5/5) 
0 a, c (5/0) 0 
b, d 
(5/0) 
P < 0.001 
E 
4.30 
1.30-8.21 
 (5/5) 
1.30 
0.73-1.94 
(5/5) 
0 a, c 
(5/0) 
0 b, d 
(5/0) 
P < 0.003 
F/E 
0.43 
0.99-2.24 
(5/5) 
0.93 
0.37-1.45 
(5/5) 
/ / NP  
PL 0 (5/0) 
0 
(5/0) 
0.66 
0-1.24 
(5/3) 
0 
(5/0)  P = 0.029 
PN 
0 
(5/0) 
0 
(5/0) 
0 
(5/0) 
0 
(5/0) NP 
DX 
0 
(5/0) 
0 
(5/0) 
1.65 a, c 
1.47-1.71 
(5/5) 
1.46 b, d 
1.32-1.60 
(5/5) 
P = 0.003 
NS – not significant; NP – not performed
Friedman Repeated Measures Analysis of Variance on Ranks was used to test the significance 
between groups.  
When the analysis was significant, to isolate the group that differs from the others, pairwise 
multiple comparison procedures (Tukey's Test) were applied. Following subscripts refer to 
statistically significant pairwise difference: a Day 0 vs Day 29; b Day 0 vs Day 40; c Day 15 vs Day 
29; c Day 15 vs Day 40 
 
 
D
ow
nl
oa
de
d 
by
 [P
oli
tec
nic
o d
i M
ila
no
 B
ibl
] a
t 0
0:3
9 1
7 J
un
e 2
01
6 
32 
 
Graphical Abstract 
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